Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12152091 | 1.00 | HSP90AA1 (0.32) | HSP90AA1TSHR | |
| SCHEMBL2359195 | 0.86 | MMP12 (0.34) | HSP90AA1TSHR | |
| SCHEMBL7302414 | 0.86 | MMP12 (0.34) | HSP90AA1TSHR | |
| SCHEMBL7296140 | 0.86 | MMP12 (0.34) | HSP90AA1TSHR | |
| SCHEMBL13847571 | 0.83 | HSP90AA1 (0.32) | HSP90AA1TSHR | |
| SCHEMBL2345036 | 0.83 | POLB (0.37) | HSP90AA1TSHR | |
| SCHEMBL5504733 | 0.83 | POLB (0.37) | HSP90AA1TSHR | |
| SCHEMBL16405292 | 0.82 | BTN3A1 (0.33) | HSP90AA1TSHR | |
| SCHEMBL16401537 | 0.82 | BTN3A1 (0.33) | HSP90AA1TSHR | |
| SCHEMBL14700385 | 0.81 | ALDH1A1 (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578733-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | RANBAXY LAB LTD (IN) | 2011-03-09 | — | — | EP | claimed |
| EP-1912953-B1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS (SI) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015074328-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | 复旦大学 | 2015-05-28 | — | — | WO | disclosed |
| US-8524914-B2 | Method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-09-03 | — | — | US | disclosed |
| US-8354530-B2 | Preparation of HMG-CoA reductase inhibitors, in particular rosuvastatin calcium, introducing L-malic acid as source of chirality for side chain; statin core moiety is consecutively coupled with chiral segment containing 4 carbon atoms and segment containing 2 carbon atoms; treating hypercholesterolemia | Lek Pharmaceuticals d. d (SI) | 2013-01-15 | — | — | US | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| EP-1578733-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | RANBAXY LAB LTD (IN) | 2011-03-09 | — | — | EP | disclosed |
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-25 | — | — | US | disclosed |
| US-7566782-B2 | condensing 1-cyano-2-[(tert-butyldimethylsilyl)oxy]-5-oxo-6-triphenylphosphanylidene hexanenitrile with 4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarbaldehyde; deprotecting, reducing, hydrolysis; improves the economics by employing less expensive reagents; productive | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-28 | — | — | US | disclosed |
| EP-2079712-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2009-07-22 | — | — | EP | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
| WO-2008053334-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| EP-1912953-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK Pharmaceuticals D.D. (SI) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CACNA1I, CACNA1S, CACNA1F | HSP90AA1 4637/4885TSHR 4503/4885 |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | HSP90AA1 4535/4885TSHR 4795/4885 |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | ACSL5, HMGCR, PCSK9 | HSP90AA1 4777/4885TSHR 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.